Nile Therapeutics have initiated a Phase IIa trial of its NPRb agonist CD-NP in acute setting heart failure patients.
Filed under: gpcr | Tagged: agonist, CD-NP, natriuretic peptide receptor B, Nile Therapeutics, nprb, phase II, Phase IIa | Leave a Comment »
Novo Nordisk have submitted a new drug application to the Ministry of Health, Labour and Welfare in Japan for the approval of liraglutide, a once-daily human GLP-1 analogue, for the treatment of people with type 2 diabetes. The drug is under review in the US and EU.
Filed under: Uncategorized | Tagged: agonist, GLP-1, Glucagon-like peptide 1, liraglutide, NN-2211, NN2211, Novo Nordisk | Leave a Comment »
Phase II data published in the July issue of Current Medical Research and Opinion show MAP Pharmaceutical’s 5HT1D agonist MAP0004, an orally inhaled and self-administered therapy, to demonstrate efficace in migraine.
Filed under: Uncategorized | Tagged: 5-HT1D, 5HT1D, agonist, MAP, MAP-0004, MAP0004, phase II | Leave a Comment »
